Superworth

RenovoRx price to book ratio RNXT

Market value divided by the book value of the company's net assets, since 2021.

Today, Nov 2, 2026
6.3×
5-year median
3.8×
Against its 5-year history
77th
percentile: 0 is its lowest day, 100 its highest
5-year range
1.0× to 18.6×
Peer median
2.3×

RenovoRx's price to book ratio is 6.3× as of Nov 2, 2026.

That is above its 5-year median of 3.8×, higher than on 77% of days in the last 5 years.

Over that time it ranged from 1.0× in Apr 2022 to 18.6× in May 2024.

The median for 8 medical instruments and supplies stocks of a similar size is 2.3×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far6.3×3.3×12.0×
20253.9×3.2×8.7×
20244.4×2.3×18.6×
20239.7×2.9×15.5×
20222.6×1.0×2.6×
20212.5×2.5×3.3×

Against its peers

Companies in Medical - Instruments & Supplies nearest RenovoRx's size, closest first, today.

CompanyPrice to book ratio
RNXTRenovoRx6.3×
APTAlpha Pro Tech0.9×
NEPHNephros2.9×
KEQUKewaunee Scientific1.3×
PDEXPro DEX3.7×
UTMDUtah Medical Products1.8×
INFUInfuSystem4.7×
EMBCEmbectan/m
TCMDTactile Systems Technology2.3×
Peer median2.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on RenovoRx

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.